



## TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26599000 Fax: + 91 79 26582100

CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores except per share data)						
Statement of Standalone Audited Financial Results for the Quarter and Nine Months ended 31-Dec-2020						
Particulars	Quarter ended			Nine Months ended		Year ended
	31-Dec-2020	30-Sep-2020	31-Dec-2019	31-Dec-2020	31-Dec-2019	31-Mar-2020
<b>Revenue</b>						
Net sales	1597	1608	1436	4890	4569	6026
Other operating income	19	32	35	93	108	142
<b>Revenue from operations (net)</b>	<b>1616</b>	<b>1640</b>	<b>1471</b>	<b>4983</b>	<b>4677</b>	<b>6168</b>
Other income	11	9	62	27	216	237
<b>Total revenue</b>	<b>1627</b>	<b>1649</b>	<b>1533</b>	<b>5010</b>	<b>4893</b>	<b>6405</b>
<b>Expenses</b>						
Cost of materials consumed	362	363	330	1078	1027	1353
Purchases of stock-in-trade	82	112	85	303	238	341
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(27)	(38)	2	(93)	(3)	(57)
Employee benefits expense	278	274	262	840	804	1062
Finance costs	87	86	106	270	334	430
Depreciation and amortisation expense	155	153	152	458	452	607
Other expenses	351	343	344	1089	1119	1552
<b>Total expenses</b>	<b>1288</b>	<b>1293</b>	<b>1281</b>	<b>3945</b>	<b>3971</b>	<b>5288</b>
<b>Profit before tax</b>	<b>339</b>	<b>356</b>	<b>252</b>	<b>1065</b>	<b>922</b>	<b>1117</b>
Tax expense						
Current Tax	60	63	42	187	158	192
Deferred Tax	1	10	(10)	19	(7)	(14)
Total tax expense	<b>61</b>	<b>73</b>	<b>32</b>	<b>206</b>	<b>151</b>	<b>178</b>
<b>Net profit for the period</b>	<b>278</b>	<b>283</b>	<b>220</b>	<b>859</b>	<b>771</b>	<b>939</b>
<b>Other comprehensive income</b>						
Items that will not be reclassified subsequently to profit or loss	(1)	4	(5)	(3)	(14)	(17)
Income tax relating to items that will not be reclassified subsequently to profit or loss	-	(1)	2	1	5	6
Items that will be reclassified subsequently to profit or loss	15	85	(44)	137	(69)	(160)
Income tax relating to items that will be reclassified subsequently to profit or loss	(5)	(30)	15	(48)	24	56
<b>Total other comprehensive income</b>	<b>9</b>	<b>58</b>	<b>(32)</b>	<b>87</b>	<b>(54)</b>	<b>(115)</b>
<b>Total comprehensive income</b>	<b>287</b>	<b>341</b>	<b>188</b>	<b>946</b>	<b>717</b>	<b>824</b>
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62	84.62	84.62
Other Equity excluding Revaluation Reserves						5036
<b>Earnings per share (of Rs. 5/- each) (not annualised for the quarter):</b>						
Basic	16.45	16.68	12.97	50.76	45.55	55.46
Diluted	16.45	16.68	12.97	50.76	45.55	55.46

**Notes:**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 08-Feb-2021. The auditor have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- 2 The Company operates in a single segment i.e Generic Formulation Business.
- 3 The listed non-convertible debentures of the company aggregating Rs. 1259 crores as at 31-Dec-2020 (previous year ended Rs. 1407 crores) are secured by way of first pari passu charge through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- 4 The Company has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its financial statement captions upto the date of approval of the financial results by the Board of Directors. The impact of Covid-19 may be different from what is estimated as at such date of approval of the financial results and the Company will continue to monitor any material changes to future economic conditions.
- 5 The Board of Directors in their meeting held on 08-Feb-2021, declared an interim equity dividend of Rs. 20 per equity share.
- 6 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

**For TORRENT PHARMACEUTICALS LIMITED**

**Place : Ahmedabad, Gujarat**  
**Date : 08-Feb-2021**

**SAMIR MEHTA**  
**Executive Chairman**